KR102935436B1 - 디아미노피리미딘 화합물을 사용한 기침 치료 방법 - Google Patents

디아미노피리미딘 화합물을 사용한 기침 치료 방법

Info

Publication number
KR102935436B1
KR102935436B1 KR1020217038551A KR20217038551A KR102935436B1 KR 102935436 B1 KR102935436 B1 KR 102935436B1 KR 1020217038551 A KR1020217038551 A KR 1020217038551A KR 20217038551 A KR20217038551 A KR 20217038551A KR 102935436 B1 KR102935436 B1 KR 102935436B1
Authority
KR
South Korea
Prior art keywords
days
cough
compound
pharmaceutically acceptable
stereoisomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217038551A
Other languages
English (en)
Korean (ko)
Other versions
KR20220007620A (ko
Inventor
옌핑 자오
홍준 왕
화이 황
위안위 지안
후이닝 량
란 안
주오 란
진 왕
링 주
옌 리우
Original Assignee
베이징 타이드 파마슈티컬 코퍼레이션 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 filed Critical 베이징 타이드 파마슈티컬 코퍼레이션 리미티드
Publication of KR20220007620A publication Critical patent/KR20220007620A/ko
Application granted granted Critical
Publication of KR102935436B1 publication Critical patent/KR102935436B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020217038551A 2019-04-30 2020-04-29 디아미노피리미딘 화합물을 사용한 기침 치료 방법 Active KR102935436B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019085180 2019-04-30
CNPCT/CN2019/085180 2019-04-30
PCT/CN2020/087686 WO2020221274A1 (zh) 2019-04-30 2020-04-29 二氨基嘧啶类化合物治疗咳嗽的方法

Publications (2)

Publication Number Publication Date
KR20220007620A KR20220007620A (ko) 2022-01-18
KR102935436B1 true KR102935436B1 (ko) 2026-03-05

Family

ID=73029672

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217038551A Active KR102935436B1 (ko) 2019-04-30 2020-04-29 디아미노피리미딘 화합물을 사용한 기침 치료 방법

Country Status (11)

Country Link
US (1) US20220211703A1 (https=)
EP (1) EP3960179B1 (https=)
JP (1) JP7665529B2 (https=)
KR (1) KR102935436B1 (https=)
CN (1) CN114007619B (https=)
AU (1) AU2020265327B2 (https=)
BR (1) BR112021021600A2 (https=)
MX (1) MX2021013338A (https=)
SG (1) SG11202111877TA (https=)
TW (1) TWI736243B (https=)
WO (1) WO2020221274A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117186068A (zh) * 2017-11-01 2023-12-08 北京泰德制药股份有限公司 P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108779119A (zh) 2016-03-25 2018-11-09 传入制药公司 嘧啶及其变体、及其用途
JP2019508445A (ja) * 2016-03-14 2019-03-28 アファレント ファーマシューティカルズ インコーポレイテッド ピリミジンおよびそのバリアント、ならびにそのための使用
WO2019085916A1 (zh) 2017-11-01 2019-05-09 北京泰德制药股份有限公司 P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2557372C (en) * 2004-03-05 2013-01-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 antagonists
EP1924564B1 (en) * 2005-09-01 2016-11-09 F.Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
AU2007304280B2 (en) 2006-10-04 2013-01-31 F. Hoffmann-La Roche Ag Process for synthesis of phenoxy diaminopyrimidine derivatives
AU2014308606B2 (en) * 2013-08-23 2017-08-03 Afferent Pharmaceuticals Inc. Diaminopyrimidine P2X3 and P2X 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough
DK3355889T3 (da) * 2015-09-29 2023-05-15 Afferent Pharmaceuticals Inc Diaminopyrimidin-p2x3- og p2x2/3-receptormodulatorer til anvendelse i behandling af hoste

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019508445A (ja) * 2016-03-14 2019-03-28 アファレント ファーマシューティカルズ インコーポレイテッド ピリミジンおよびそのバリアント、ならびにそのための使用
CN108779119A (zh) 2016-03-25 2018-11-09 传入制药公司 嘧啶及其变体、及其用途
JP2019510025A (ja) * 2016-03-25 2019-04-11 アファレント ファーマシューティカルズ インコーポレイテッド ピリミジンおよびそのバリアント、ならびにそのための使用
WO2019085916A1 (zh) 2017-11-01 2019-05-09 北京泰德制药股份有限公司 P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途

Also Published As

Publication number Publication date
EP3960179B1 (en) 2026-03-18
WO2020221274A1 (zh) 2020-11-05
CN114007619A (zh) 2022-02-01
SG11202111877TA (en) 2021-11-29
BR112021021600A2 (pt) 2022-01-04
CA3138780A1 (en) 2020-11-05
US20220211703A1 (en) 2022-07-07
TWI736243B (zh) 2021-08-11
CN114007619B (zh) 2024-08-06
JP7665529B2 (ja) 2025-04-21
AU2020265327A1 (en) 2021-12-16
JP2022530890A (ja) 2022-07-04
EP3960179A4 (en) 2023-01-25
EP3960179A1 (en) 2022-03-02
MX2021013338A (es) 2022-01-24
KR20220007620A (ko) 2022-01-18
AU2020265327B2 (en) 2025-09-11
TW202106302A (zh) 2021-02-16

Similar Documents

Publication Publication Date Title
US12582653B2 (en) Method for treating idiopathic pulmonary fibrosis
KR102906316B1 (ko) 지방간 질환 및/또는 지방간염의 치료 방법
KR102935436B1 (ko) 디아미노피리미딘 화합물을 사용한 기침 치료 방법
KR102935431B1 (ko) 디아미노피리미딘 화합물을 사용하여 자궁내막증-관련 통증 치료 방법
JP7803924B2 (ja) 造血幹細胞移植によって引き起こされる移植片対宿主病を治療する方法
HK40062124A (en) Method for treating cough by using diaminopyrimidine compound
EP4591863A1 (en) Method for treating pneumoconiosis
CA3138780C (en) Method for treating cough by using diaminopyrimidine compound
HK40063168A (en) Method for treating cough by using diaminopyrimidine compound
HK40063168B (zh) 二氨基嘧啶类化合物治疗咳嗽的方法
HK40064686A (en) Method for treating idiopathic pulmonary fibrosis
HK40121343A (zh) 治疗特发性肺纤维化的方法
HK40086216A (en) Method for treating graft versus host disease caused by hematopoietic stem cell transplantation
HK40058942A (en) Method for treating fatty liver disease and/or steatohepatitis
HK40063173A (en) Method for treating idiopathic pulmonary fibrosis
HK40063619B (zh) 二氨基嘧啶类化合物治疗子宫内膜异位相关的疼痛的方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P18-X000 Priority claim added or amended

St.27 status event code: A-2-2-P10-P18-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)